Tone mix
Week by week 52 weeks
Share of Genmab A/S ADS's 216 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Feb 2, 2026 · tone -99EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)-109
- Week of Mar 9, 2026 · tone +99Narrow-Moat Genmab's Royalty Revenue Maintains Near-Term Growth as Pipeline Advancement Progresses+80
- Week of Jan 26, 2026 · tone -50EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)-77
- Week of Apr 20, 2026 · tone +100Genmab A/S (NASDAQ:GMAB) Upgraded by BNP Paribas Exane to "Strong-Buy" Rating+69
- Week of Apr 13, 2026 · tone +100Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln+68
- Week of Aug 24, 2026 · tone +100Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?+66
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Genmab A/S ADS in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 21 | +57 |
| Last 30 sessions | 55 | +60 |
| Last 90 sessions | 92 | +47 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
6 headlines, average tone 0: 1 positive, 4 neutral and 1 negative. Showing all 6.
- www.rttnews.com · 1 outletGenmab Profit Drops In Q3, Maintains FY26 Revenue OutlookNegative
- www.dailypolitical.com · 1 outletGenmab A/S (OTCMKTS:GNMSF) Posts Quarterly Earnings Results, Beats Estimates By $2.15 EPSPositive
- www.dailypolitical.com · 1 outletFinancial Contrast: Lunai Bioworks (NASDAQ:LNAI) versus Genmab A/S (NASDAQ:GMAB)Neutral
- www.manilatimes.net · 1 outletGenmab Announces Financial Results for the Nine Months of 2026Neutral
- www.investegate.co.uk · 1 outletGenmab Announces Financial Results for the Nine Months of 2026 | Company AnnouncementNeutral
- www.finanznachrichten.de · 1 outletGenmab A/S: Genmab Announces Financial Results for the Nine Months of 2026Neutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab Profit Drops In Q3, Maintains FY26 Revenue Outlook | www.rttnews.com | 1 | Negative |
| Genmab A/S (OTCMKTS:GNMSF) Posts Quarterly Earnings Results, Beats Estimates By $2.15 EPS | www.dailypolitical.com | 1 | Positive |
| Financial Contrast: Lunai Bioworks (NASDAQ:LNAI) versus Genmab A/S (NASDAQ:GMAB) | www.dailypolitical.com | 1 | Neutral |
| Genmab Announces Financial Results for the Nine Months of 2026 | www.manilatimes.net | 1 | Neutral |
| Genmab Announces Financial Results for the Nine Months of 2026 | Company Announcement | www.investegate.co.uk | 1 | Neutral |
| Genmab A/S: Genmab Announces Financial Results for the Nine Months of 2026 | www.finanznachrichten.de | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.investegate.co.uk · 1 outletGenmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting | Company AnnouncementNeutral
- www.finanznachrichten.de · 1 outletGenmab A/S: Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual MeetingNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting | Company Announcement | www.investegate.co.uk | 1 | Neutral |
| Genmab A/S: Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting | www.finanznachrichten.de | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.cnbc.com · 1 outletGenmab cancer drug wins fuel shift to owning more medicinesPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab cancer drug wins fuel shift to owning more medicines | www.cnbc.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
3 headlines, average tone +66: 2 positive, 1 neutral and 0 negative. Showing all 3.
- www.dailypolitical.com · 1 outletGenmab A/S (NASDAQ:GMAB) Price Target Raised to $80.00Positive
- www.themarketsdaily.com · 1 outletGenmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer LaunchesPositive
- www.themarketsdaily.com · 1 outletGenmab A/S (NASDAQ:GMAB) vs. Novavax (NASDAQ:NVAX) Critical SurveyNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab A/S (NASDAQ:GMAB) Price Target Raised to $80.00 | www.dailypolitical.com | 1 | Positive |
| Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches | www.themarketsdaily.com | 1 | Positive |
| Genmab A/S (NASDAQ:GMAB) vs. Novavax (NASDAQ:NVAX) Critical Survey | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 30, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.biopharmadive.com · 1 outletGenmab soars to record highs after cancer drug succeeds in key trialPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab soars to record highs after cancer drug succeeds in key trial | www.biopharmadive.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Genmab A/S ADS, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.